Status:
UNKNOWN
A Study of QLS31905 in Patients With Advanced Solid Tumors
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Conditions:
Advanced Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This is a multi-center, open-label design to evaluate the safety and tolerance of QLS31905 in patients with advanced solid tumors, together with an assessment of pharmacokinetic characteristics and ef...
Eligibility Criteria
Inclusion
- Written informed consent.
- ≥18 years.
- Female or male.
- ECOG performance status score 0 or 1.
- Histologically or cytologically confirmed diagnosis of advanced solid tumors.
- Adequate haematological, hepatic and renal function.
Exclusion
- Any anticancer therapy or immunotherapy within 4 weeks prior to the start of study treatment.
- Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.
- Patients with a history of monoclonal antibody allergic reaction.
- Known human immunodeficiency virus infection or known symptomatic hepatitis.
Key Trial Info
Start Date :
October 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT05278832
Start Date
October 25 2021
End Date
December 31 2023
Last Update
March 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142